Inhibikase Therapeutics slahes deal size ahead of IPO

Twelve-year-old early-stage neuro biotech Inhibikase Therapeutics has nearly halved its shares offering ahead of a now lowered IPO.

The Atlanta-based biotech had first planned to raise $25 million by offering 2.3 million shares at the $10 to $12 range, but, while keeping the range, it has slashed its offering by 40% down to 1.4 million.